Cargando…

Current and Emerging Therapies for the Treatment of Multiple Sclerosis: Focus on Cladribine

Multiple Sclerosis (MS) is a chronic inflammatory, immune-mediated, demyelinating disorder of the central nervous system with a heterogeneous clinical presentation and pathology in which activated lymphocytes play an important role in mediating tissue damage. Until recently, all first line therapies...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schreiner, Teri L., Miravalle, Augusto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2012
Materias:	Expert Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619698/ https://www.ncbi.nlm.nih.gov/pubmed/23650463 http://dx.doi.org/10.4137/JCNSD.S5128

Ejemplares similares

Emerging therapies for treatment of multiple sclerosis
por: Corboy, John R, et al.
Publicado: (2010)

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine
por: Warnke, Clemens, et al.
Publicado: (2010)

Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets
por: Gasperini, Claudio, et al.
Publicado: (2010)

Recent advances in the treatment of multiple sclerosis
por: Bennett, Jeffrey L, et al.
Publicado: (2010)

New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come
por: Nicholas, J., et al.
Publicado: (2012)

Depressive symptoms, anxiety and cognitive impairment: emerging evidence in multiple sclerosis
por: Margoni, Monica, et al.
Publicado: (2023)

The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
por: Hermann, Robert, et al.
Publicado: (2018)

Remyelination Therapy in Multiple Sclerosis
por: Harlow, Danielle E., et al.
Publicado: (2015)

Glatiramer acetate in the treatment of multiple sclerosis
por: Tselis, Alex, et al.
Publicado: (2007)

The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review
por: Rammohan, Kottil, et al.
Publicado: (2020)

Emerging treatments for premature ejaculation: focus on dapoxetine
por: Hellstrom, Wayne JG
Publicado: (2009)

Current and Emerging Pharmacotherapies for the Treatment of Relapsed Small Cell Lung Cancer
por: Nair, Binu S., et al.
Publicado: (2011)

The role of glatiramer acetate in the early treatment of multiple sclerosis
por: Brandes, David W
Publicado: (2010)

Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
por: Savic, Radojka M., et al.
Publicado: (2017)

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021)

Molecular signature associated with cladribine treatment in patients with multiple sclerosis
por: Fissolo, Nicolas, et al.
Publicado: (2023)

Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis
por: Murphy, Julie A, et al.
Publicado: (2010)

Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin’s Lymphoma: Focus on Brentuximab Vedotin
por: Furtado, Michelle, et al.
Publicado: (2012)

Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
por: Giovannoni, Gavin, et al.
Publicado: (2022)

Emerging treatments in the management of bipolar disorder – focus on risperidone long acting injection
por: El-Hage, Wissam, et al.
Publicado: (2010)

COVID-19 in Cladribine-treated patient with multiple sclerosis
por: Haham, Nitsan, et al.
Publicado: (2021)

Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells
por: Ceronie, Bryan, et al.
Publicado: (2018)

Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment
por: Schönfelder, Kristina, et al.
Publicado: (2021)

Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?
por: Yalin, Nefize, et al.
Publicado: (2020)

Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
por: Clavelou, Pierre, et al.
Publicado: (2023)

Cladribine tablets’ potential role as a key example of selective immune reconstitution therapy in multiple sclerosis
por: Boyko, Alexey N, et al.
Publicado: (2018)

Review of the clinical evidence for interferon β 1a (Rebif(®)) in the treatment of multiple sclerosis
por: Manfredonia, Francesco, et al.
Publicado: (2008)

Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab
por: Patel, Akshar N., et al.
Publicado: (2012)

Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis
por: Nabizadeh, Fardin, et al.
Publicado: (2023)

Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
por: Michels, Renée Else, et al.
Publicado: (2019)

Oral cladribine treatment and idiosyncratic drug-induced liver injury in multiple sclerosis
por: Rakers, Florian, et al.
Publicado: (2023)

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients
por: Allen-Philbey, Kimberley, et al.
Publicado: (2021)

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
por: Buttari, Fabio, et al.
Publicado: (2021)

Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets
por: Moiola, Lucia, et al.
Publicado: (2022)

Effect of Cladribine on Neuronal Apoptosis: New Insight of In Vitro Study in Multiple Sclerosis Therapy
por: Ruggieri, Maddalena, et al.
Publicado: (2020)

The effect of cladribine on immunoglobulin levels compared to B cell targeting therapies in multiple sclerosis
por: Lycett, Mitchell J, et al.
Publicado: (2023)

Correction to: Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
por: Michels, Renée Else, et al.
Publicado: (2020)

Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis
por: Oh, Jiwon, et al.
Publicado: (2021)

No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine
por: Pakpoor, Julia, et al.
Publicado: (2015)

Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis
por: Afolabi, Dayo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6j53ehlglf8hagp145kpqvmld1